AzTrials
AzTrials

Colorectal CancerPhase 4PEGNCT00626054

Comparison of Two Methods of Administration of a PEG Solution

A Phase 4 study testing PEG solution in a single dose of 3 liters and PEG solution in people with Colorectal Cancer, run by Rabin Medical Center at 1 site in Israel.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to compare the effectiveness (quality of bowel cleansing) and ease of use (patient satisfaction) of two methods of administration of a precolonoscopy PEG solution in hospitalized patients. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Colorectal Cancer
What is being tested?
PEG solution in a single dose of 3 liters and PEG solution
Could I receive a placebo?
No, everyone receives an active treatment
How many people
400 participants
Where
1 siteIsrael
Study dates
Mar 2009to Mar 2012
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 18-80 years
  • ability to understand and complete the questionnaires
  • ability to participate in all stages of the research

Who cannot join

  • Previous colon surgery
  • endoscopic procedures under full anesthesia
  • known sensitivity to the PEG solution
  • terminal renal or cardiac insufficiency
  • inability to sign the informed consent form

Trial locations and contacts

1 site in 1 country.

Israel1 site
  • Rabin Medical Center

    Petah Tikva, 49100

Other trials in Israel

About this study

Official title: Comparison of Two Methods of Administration of a PEG Solution During Bowel Preparation for Colonoscopy in Hospitalized Patients

The purpose of this study is to compare the effectiveness (quality of bowel cleansing) and ease of use (patient satisfaction) of two methods of administration of a precolonoscopy PEG solution in hospitalized patients.

Read the detailed description

Background and rationale of the research

Colonoscopy is an endoscopic examination whereby the physician can visually inspect the interior lining of the colon. It is the most efficient and accurate means of identifying, either directly or by biopsy, neoplasms in the large intestine and inflammatory processes, infections, or ischemia involving the whole colon and the distal small intestines. In addition, during the procedure, certain endoscopic treatments may be performed, such as removal of precancerous polyps and cauterization of bleeding sites such as vascular malformations by electrocoagulation.

Proper preparation of the bowel prior to colonoscopy is crucial to the quality of the examination. Suboptimal preparation can adversely affect the ability of the examiner to detect abnormalities in the small and large intestine or to carry out various endoscopic treatments. In some cases, poor preparation may necessitate canceling the procedure and rescheduling the patient for a repeated test.

To properly clear the bowel, patients must strictly adhere to a special diet and drink a laxative solution as directed. The physician selects the specific type of laxative solution from among those that are currently available on the basis of the patient's age and underlying diseases. At present, polyethylene glycol (PEG), owing to its good safety profile and relative lack of complications, is recommended in older patients (65 years or more), patients with hypertension or renal or cardiac insufficiency, and patients being treated with diuretics and ACE inhibitors. However, a major disadvantage of PEG is its difficulty of use, which involves bad taste and drinking 3 liters within a short period of time on the day before the examination.

Several recent studies in the medical literature have reported that in ambulatory patients, dividing the oral laxative solution into 2 doses taken at different times is more effective than drinking the whole amount in one session. On the basis of these findings, and given that the quality of the bowel preparation is known to be poorer in hospitalized than in ambulatory patients, we sought to determine if dividing the laxative dose will yield better results in hospitalized patients as well. It should be noted that laxative solutions constitute the most accepted method of preparing the bowel for colonoscopy and that in the present study, the sole difference from standard practice was the method of administration, namely a single or a split dose.

Aim of the study The purpose of this study is to compare the effectiveness (quality of bowel cleansing) and ease of use (patient satisfaction) of two methods of administration of a precolonoscopy PEG solution in hospitalized patients.

Method

Study design: Prospective, comparative, randomized

End points:

Primary - Cleanliness of the bowel, as determined by the examiner, and ease of use, as determined by a patient satisfaction questionnaire in the two study arms Secondary - Effect of external factors (demographic parameters, length of hospitalization, procedural diagnosis) on the quality of the bowel preparation.

Study sample: Four hundred hospitalized patients scheduled for a colonoscopy examination as part of their in-hospital work-up.

Inclusion criteria: Age 18-80 years; ability to understand and complete the questionnaires; ability to participate in all stages of the research.

Exclusion criteria: Previous colon surgery, previous endoscopic procedures under full anesthesia, known sensitivity to the PEG solution, terminal renal or cardiac insufficiency, inability to sign the informed consent form Colonoscopy: All patients will perform the precolonoscopy bowel preparation by one of two methods, according to the study design, followed by colonoscopy at the Gastrolenterology Institute of Rabin Medical Center

Questionnaires:

Demographic questionnaire - age, sex, weight, height, years of education Patient satisfaction questionnaire - ease of preparation and related symptoms In addition, physicians will rate the degree of bowel visibility after the procedure on a standard scale.

Study design:

The study sample will include hospitalized patients scheduled for colonoscopy. The physicians conducting the research will obtain informed consent from all candidates for the study prior to their enrollment.

At onset of the study, the participants will complete a demographic questionnaire in the presence of a member of the research team. Items will include age, sex, height, weight, and years of education.

Study participants will be randomly divided into 2 groups. Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test. Group 2 will receive half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test. The randomization will be performed at the Gastroenterology Institute. The secretary of the Institute will then inform the nurses/attendants in the various hospitalization departments which of the two procedures to apply to each individual patient. Before the procedure, the patients will complete a demographic questionnaire in the presence of a member of research team. The physician performing the colonoscopies will be blinded to the group allocation. After completing the colonoscopy, the physician will rate the quality of the bowel preparation in the patient's medical file according to the Aronchick scale, as follows:

Score Description 0 - excellent More than 95% of the intestines visible

  1. - good Large amount of transparent fluid requiring suction; more than 90% of intestines visible
  2. - fair Semisolid stool requiring suction/flushing; more than 90% of intestines visible
  3. - poor Semisolid stool difficult or impossible to remove; less than 90% of intestines visible
  4. - failed Repeated test required

Following the procedure, study participants will be asked to rate their satisfaction with the ease of use of the bowel preparation and the severity of symptoms related to it (e.g., stomach pain, nausea) on a VAS scale.

Colonoscopy method:

At the time of referral for colonoscopy, patients will receive a preliminary explanation of the test, of the alternative examinations currently available, and of any possible complications of the test. On the day of the colonoscopy, after receiving additional explanations from the attending gastroenterologist, patients will be asked to sign an informed consent form. The colonoscopy examination will be performed with patients lying on their left side; a sedative will be administered intravenously. During the procedure, the patient may feel cramping and discomfort from the infusion of air into the colon. The duration of the examination will about 30 minutes, depending on the structure of the colon, the amount of visibility consequent to the bowel preparation, and the degree of patient cooperation; the last two factors are essential for the success of the procedure. The endoscopic device will be carefully cleaned and sterilized between examinations in accordance with routine practice at our institute and accepted standards in developed countries.

Statistical analysis

On the basis of reported means and standard deviations in the medical literature, assuming a 75% compliance rate and type 1 error (α) of 0.05, a study sample of 400 hospitalized patients will yield a statistical power of more than 80%. The sample will be divided into two treatment groups using the computerized Research Randomizer 2007 (http://www.randomizer.org/) Independent t test will be used to compare means of continuous variables between the two groups, and chi-square test will be used to compare proportions. Nonparametric Mann-Whitney test will be used to analyze the level of preparation and bowel cleanliness, ranked on an ordinal scale, between the groups. All test will be two-sided; statistical significance will be set at p<0.05. All analyses will be performed with SPSS software, version 15.

Participating researchers

Gastroenterology Institute: Dr. Ram Dickman, Dr. Gal Eyal, Dr. Zvidi Ibrahim, Dr. Ofer Ben Bassat, Dr. Wilkin Alexander, Dr. Zohar Levy, Dr. Michal Cohen, Dr. Gerald Fraser, Prof. Yaron Niv, Dr. Boris Sapoznikov, Dr. Irit Avni-Biran, Nechama Horev, Melli Mor, Negba Segal, Shlomit Flaut, Yafit Honen, Igor Bogoslavsky, Ilana Morad.

Schedule

The study is planned for a two-year period:

Patient enrollment until mid-2009 Data collection and analysis until end 2008-beginning 2009

Ethics

Patient anonymity will be maintained.

Being tested
PEG solution in a single dose of 3 liters, PEG solution
Keywords
Colonoscopy, PEG Solution
Medical subject headings
Colorectal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PEG solution in a single dose of 3 litersDrug

    Also called Meroken New

    Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.

  • PEG solutionDrug

    Also called Meroken New

    PEG solution: half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test

Study groups in NCT00626054
Study groupRoleWhat they receive
1Active comparatorGroup 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
Receives: Drug: PEG solution in a single dose of 3 liters
2Active comparatorGroup 2 will receive half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test.
Receives: Drug: PEG solution

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cleanliness of the bowel, as determined by the examiner, and ease of use, as determined by a patient satisfaction questionnaire in the two study arms

    Measured: 1 year

Secondary outcomes (1)
  1. Effect of external factors (demographic parameters, length of hospitalization, procedural diagnosis) on the quality of the bowel preparation

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Feb 2008 (estimated)
  2. Study startMar 2009
  3. Primary completionDec 2011
  4. Study completionMar 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
400 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00626054
Sponsor's protocol ID
004907
Acronym
PEG
Status last verified
Apr 2016
First submitted
20 Feb 2008
Last updated
13 Apr 2016
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing PEG solution in a single dose of 3 liters and PEG solution in people with Colorectal Cancer, run by Rabin Medical Center at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Apr 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cleanliness of the bowel, as determined by the examiner, and ease of use, as determined by a patient satisfaction questionnaire in the two study arms (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in